Group Art Unit: Not yet Assigned

Examiner: Not yet Assigned

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

Daniel Nahon

Application No.:

Not yet Assigned

Filing Date:

Herewith

Entitled:

METHOD AND APPARATUS

FOR PREVENTING ATRIAL

FIBRILLATION

Docket No.:

21819-205U

INFORMATION DISCLOSURE STATEMENT

Mail Stop Patent Application Commissioner For Patents P.O. Box 1450 Alexandria, VA 22312-1450

Dear Sir:

It is desired to cite for the record in this application the enclosed articles, United States and foreign patents listed on the attached copy of Form PTO/SB/08A and PTO/SB/08B. The paragraph(s) marked below are applicable to this Information Disclosure Statement.

The attached Form PTO/SB/08A and PTO/SB/08B provides a listing of information which may be relevant to the subject application. This Information Disclosure Statement is not intended as a representation that better art is not available, or that the information provided is prior art.

Application No.:Not yet Assigned Filing Date:Herewith Atty. Docket No. 21819-205U

[X] (1) The enclosed Information Disclosure Statement is being filed within three months of the filing date or within three months of the date of entry of the national stage of the above-identified application. Accordingly, Applicant(s) believes that no fee or certification is required.

[](1a) The enclosed Information Disclosure Statement is being filed before the mailing of a first Office action on the merits under 37 C.F.R. §1.97(b)(3); or before the mailing of a first Office action after the filing of a request for continued examination under §1.114. Accordingly, Applicant(s) believes that no fee or certification is required.

[](1b) Pursuant to 37 C.F.R. §1.97(c), the enclosed Information Disclosure Statement is being filed before the mailing date of a final action or a notice of allowance and is accompanied by the fee set forth in § 1.17(p).

[](2) Pursuant to 37 C.F.R. § 1.97(d), Applicant states that the issue fee has not been paid and that a certification under 37 C.F.R. §1.97(e) is provided herein, along with the fee of \$180.00

CERTIFICATION UNDER 37 C.F.R. §1.97(e) (1)

required under 37 C.F.R. §1.17(p).

[] (3) The undersigned hereby certifies that each item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application mailed not more than three months prior to the filing of this statement.

CERTIFICATION UNDER 37 C.F.R. §1.97(e) (2)

[] (4) The undersigned hereby certifies that no item of information contained in the attached Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, after making reasonable inquiry, was known to any individual having a duty of disclosure as set forth in 37 C.F.R. §1.56(c) more than three months prior to the filing of this statement.

The filing of this Information Disclosure Statement is not representation by the undersigned as to the personal knowledge of the contents of every word or phrase of the material enclosed or that reliance on other suitably trained professionals has not been made.

If a search report of a searching agency is enclosed identifying the nature of the relevance of each document, such a designation is deemed to satisfy Rule 98(a) (3) even if in a foreign language, since the few terms of relevance therein are deemed of universal cognizance.

However, Applicant does not necessarily adopt the position reflected by that report.

It is respectfully requested that the enclosed references be considered by the Examiner and that a copy of the enclosed Form PTO/SB/08A and PTO/SB/08B be initialed and returned to us indicating that such information has been considered.

Application No.: Not yet Assigned Filing Date: Herewith

Atty. Docket No. 21819-205U

The Commissioner is hereby authorized to credit overpayments or charge payment of any additional fees associated with this communication to Deposit Account No. 502104.

Respectfully submitted,

Dated: March 31, 2004

By:

John Christopher Res. No. 37,596

Attorney for Applicant(s

Christopher & Weisberg, P.A. 200 East Las Olas Boulevard

Suite 2040

Fort Lauderdale, Florida 33301

Tel: (954) 828-1488 Fax: (954) 828-9122 Customer No. 31292

17547

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO					–	Complete if Known			
						Application	Number	Not yet Assigned	
INFORMATION DISCLOSURE						Filing Date		Herewith	
STATEMENT BY APPLICANT (use as many sheets as necessary)						First Named Inventor Art Unit Examiner Name		Daniel Nahon Not yet Assigned Not yet Assigned	
Sheet		1	of	3		Attorney Docket Number		21819-205U	
			.		J.S. PATEN	T DOCUMEN	TS	l	
Examiner Initials •	Cite No.1	Documen				Publication Date MM-DD-YYYY	Name of Paten Applicant of Cit		Pages, Columns, Lines, Where Relevant
		Number- Kind Code 2 (if known)				Document		Passages or Relevant Figures Appear	
		US-6,51	1,500 B1			01/28/2003	M.M. Rahme		
		US-6,56	4,096 B2		(05/13/2003	R.A. Mest		

	Cite	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	No.¹	Country Code ^{3 - Number 4} Kind Code ⁵ (if known)		Document		
						_
					-	\vdash
			*	0 - 0	<u></u>	╁
Examiner	: Signati	150) Pate Considered		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form	n 1449B/PTO			Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	Not yet Assigned		
				Filing Date	Herewith		
				First Named Inventor	Daniel Nahon		
				Group Art Unit	Not yet Assigned		
(use as many sheets as necessary))	Examiner Name	Not yet Assigned		
Sheet	2	of	3	Attorney Docket Number	21819-205U		

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²						
		GARDNER, E., et al., The Nerve Supply and Conducting System of the Human Heart	}						
		at the End of the Embryonic Period Proper, J. Anat. (1976), 121, 3, pp. 571-587.							
		GULBENKIAN, S., et al., Peptidergic Innervation of Human Epicardial Coronary							
		Arteries, Circulation Research, Vol. 73, No. 3, September 1993, pp. 579-588.							
		KALMAN, J.M., et al., Atrial Fibrillation After Coronary Artery Bypass Grafting is							
		Associated with Sympathetic Activation, Ann. Thorac. Surg., 1995;60:1709-15, pp. 1709-1715.							
		ARANKI, S.F., et al., Predictors of Atrial Fibrillation After Coronary Artery Surgery,							
		Circulation. 1996;94:390-397, pp. 390-397.							
		HOGUE, C.W. Jr., et al., RR Interval Dynamics Before Atrial fibrillation in Patients							
		after Coronary Artery Bypass Graft Surgery, Circulation. 1998;98:429-434, pp. 429-							
		434.							
		PASIC, M., et al., Surgery for Acquired Cardiovascular Disease, The Journal of							
		Thoracic and Cardiovascular Surgery, Vol. 118, Number 2, August 1999, pp. 287-							
		296.	ļ						
		DOSHI, R.N., et al., Relation Between Ligament of Marshall and Adrenergic Atrial							
		<u>Tachyarrhythmia</u> , <i>Circulation</i> .1999;100:876-883, pp. 876-883.							
		JAYACHANDRAN, J.V., et al., <u>Atrial fibrillation Produced by Prolonged Rapid</u>							
		Atrial Pacing is Associated with Heterogeneous Changes in Atrial Sympathetic							
		<u>Innervation</u> , Circulation.2000;101:1185-1191, pp. 1185-1191.							
		PAUZA, D.H., et al., Morphology, Distribution, and Variability of the Epicardiac							
		Neural Ganglionated Subplexuses in the Human Heart, The Anatomical Record							
		259:353-382 (2000), pp. 353-382.							
		HOGUE, C.W., Jr., et al., Atrial fibrillation After Cardiac Operation: Risks,							
		Mechanisms, and Treatment, Ann. Thorac Surg. 2000;69:300-6 (2000).							
		WU, T-J, et al, <u>Pulmonary Veins and Ligament of Marshall as Sources of Rapid</u>							
		Activations in a Canine Model of Sustained Atrial Fibrillation, Circulation.							
		2001;103:1157-1163.	<u>l</u>						
		Date Considered							
Examiner Signature	gnature								

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents Washington, DC 20231.

Substitute for f	orm 1449B/PT	0		Complete if Known		
INFOR	MATIO	N DIS	CLOSURE	Application Number	Not yet Assigned	
				Filing Date	Herewith	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Daniel Nahon	
				Group Art Unit	Not yet Assigned	
(use as many sheets as necessary)		Examiner Name	Not yet Assigned			
Sheet	3	of	3	Attorney Docket Number	21819-205U	

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	Π						
Initials *	No. ¹	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²						
		CRESWELL, L.L., et al., Postoperative Atrial Fibrillation: An Old Problem Crying for							
		New Solutions, The Journal of Thoracic and cardiovascular Surgery, March 2003; Vol. 125:S20-3, pp. S20-223							
	 	BAUERNSCHMITT, R., et al., Depression of a Baroreflex Sensitivity After Cardiac							
		Surgery, Programme of the 2 nd EACTS/ESTS Joint Meeting: Abstracts, Abstract No. 195, October 14, 2003, p. 480							
	+		-						
		PAPPONE, C., et al., <u>Pulmonary Vein Denervation Enhances Long-Term Benefit</u> After Circumferential Ablation for Paroxysmal Atrial Fibrillation, <i>Circulation</i> .							
		2004;109:327-334, pp. 327-334.							
		MELO, J., et al., Ventral Cardiac Denervation Reduces the Incidence of Atrial							
		Fibrillation After Coronary Artery Bypass Grafting, The Journal of Thoracic and							
		Cardiovascular Surgery, Vol. 127, Number 2, (2004);127:511-6, pp. 511-516.							
		·							
	1								
			_						
		Date Considered	<u> </u>						

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents Washington, DC 20231. Patents Washington, DC 20231.